Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

31,888 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.
Wharton S, Blevins T, Connery L, Rosenstock J, Raha S, Liu R, Ma X, Mather KJ, Haupt A, Robins D, Pratt E, Kazda C, Konig M; GZGI Investigators. Wharton S, et al. Among authors: ma x. N Engl J Med. 2023 Sep 7;389(10):877-888. doi: 10.1056/NEJMoa2302392. Epub 2023 Jun 23. N Engl J Med. 2023. PMID: 37351564 Clinical Trial.
Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes.
Pratt E, Ma X, Liu R, Robins D, Coskun T, Sloop KW, Haupt A, Benson C. Pratt E, et al. Among authors: ma x. Diabetes Obes Metab. 2023 Sep;25(9):2642-2649. doi: 10.1111/dom.15150. Epub 2023 Jun 1. Diabetes Obes Metab. 2023. PMID: 37264711 Clinical Trial.
Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participants.
Pratt E, Ma X, Liu R, Robins D, Haupt A, Coskun T, Sloop KW, Benson C. Pratt E, et al. Among authors: ma x. Diabetes Obes Metab. 2023 Sep;25(9):2634-2641. doi: 10.1111/dom.15184. Epub 2023 Jun 21. Diabetes Obes Metab. 2023. PMID: 37344954 Clinical Trial.
The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470).
Hamdouchi C, Kahl SD, Patel Lewis A, Cardona GR, Zink RW, Chen K, Eessalu TE, Ficorilli JV, Marcelo MC, Otto KA, Wilbur KL, Lineswala JP, Piper JL, Coffey DS, Sweetana SA, Haas JV, Brooks DA, Pratt EJ, Belin RM, Deeg MA, Ma X, Cannady EA, Johnson JT, Yumibe NP, Chen Q, Maiti P, Montrose-Rafizadeh C, Chen Y, Reifel Miller A. Hamdouchi C, et al. Among authors: ma x. J Med Chem. 2016 Dec 22;59(24):10891-10916. doi: 10.1021/acs.jmedchem.6b00892. Epub 2016 Nov 11. J Med Chem. 2016. PMID: 27749056
Discovery of LY3104607: A Potent and Selective G Protein-Coupled Receptor 40 (GPR40) Agonist with Optimized Pharmacokinetic Properties to Support Once Daily Oral Treatment in Patients with Type 2 Diabetes Mellitus.
Hamdouchi C, Maiti P, Warshawsky AM, DeBaillie AC, Otto KA, Wilbur KL, Kahl SD, Patel Lewis A, Cardona GR, Zink RW, Chen K, Cr S, Lineswala JP, Neathery GL, Bouaichi C, Diseroad BA, Campbell AN, Sweetana SA, Adams LA, Cabrera O, Ma X, Yumibe NP, Montrose-Rafizadeh C, Chen Y, Miller AR. Hamdouchi C, et al. Among authors: ma x. J Med Chem. 2018 Feb 8;61(3):934-945. doi: 10.1021/acs.jmedchem.7b01411. Epub 2018 Jan 5. J Med Chem. 2018. PMID: 29236497
31,888 results
You have reached the last available page of results. Please see the User Guide for more information.